Future studies should focus on determining the long-term outcomes of PDE-5 inhibitors in high-risk groups, such as patients with HFpEF and pulmonary hypertension, or individuals recovering from a stroke with compromised cerebral blood flow. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.